Organization | Azienda ULSS 12 Veneziana

Azienda ULSS 12 Veneziana Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial

2014

NCT02067143

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Now

Alternative names

Azienda ULSS 12 "Veneziana" U.O. Ematologia Direttore Renato Bassan

Active Ingredients

Drugs in Phase 2 Trials (10)

allogeneic stem cells (1 trial)

blinatumomab (blincyto) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

cytarabine (cytosar-u) (1 trial)

idarubicin (idamycin) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

mercaptopurine (purinethol) (1 trial)

prednisone (meticorten) (1 trial)

vincristine (oncovin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Philadelphia Chromosome (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 2
# of Trial APIs: 10